122 related articles for article (PubMed ID: 11805730)
1. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Price DK; Ando Y; Kruger EA; Weiss M; Figg WD
Ther Drug Monit; 2002 Feb; 24(1):104-10. PubMed ID: 11805730
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs.
Peach ML; Beedie SL; Chau CH; Collins MK; Markolovic S; Luo W; Tweedie D; Steinebach C; Greig NH; Gütschow M; Vargesson N; Nicklaus MC; Figg WD
Molecules; 2020 Dec; 25(23):. PubMed ID: 33276504
[TBL] [Abstract][Full Text] [Related]
4. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Kruger EA; Duray PH; Tsokos MG; Venzon DJ; Libutti SK; Dixon SC; Rudek MA; Pluda J; Allegra C; Figg WD
Biochem Biophys Res Commun; 2000 Feb; 268(1):183-91. PubMed ID: 10652234
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors derived from thalidomide.
Noguchi T; Fujimoto H; Sano H; Miyajima A; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2005 Dec; 15(24):5509-13. PubMed ID: 16183272
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
Bauer KS; Dixon SC; Figg WD
Biochem Pharmacol; 1998 Jun; 55(11):1827-34. PubMed ID: 9714301
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
[TBL] [Abstract][Full Text] [Related]
8. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
Lepper ER; Ng SS; Gütschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD
J Med Chem; 2004 Apr; 47(9):2219-27. PubMed ID: 15084120
[TBL] [Abstract][Full Text] [Related]
9. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation.
Marks MG; Shi J; Fry MO; Xiao Z; Trzyna M; Pokala V; Ihnat MA; Li PK
Biol Pharm Bull; 2002 May; 25(5):597-604. PubMed ID: 12033499
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells.
Tamilarasan KP; Kolluru GK; Rajaram M; Indhumathy M; Saranya R; Chatterjee S
BMC Cell Biol; 2006 Apr; 7():17. PubMed ID: 16584574
[TBL] [Abstract][Full Text] [Related]
11. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
Chowdhury G; Shibata N; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2014 Jan; 27(1):147-56. PubMed ID: 24350712
[TBL] [Abstract][Full Text] [Related]
12. The rat aortic ring assay for in vitro study of angiogenesis.
Go RS; Owen WG
Methods Mol Med; 2003; 85():59-64. PubMed ID: 12710197
[No Abstract] [Full Text] [Related]
13. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Mahony C; Erskine L; Niven J; Greig NH; Figg WD; Vargesson N
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12703-8. PubMed ID: 23858438
[TBL] [Abstract][Full Text] [Related]
14. Effects of thalidomide, cytochrome P-450 and TNF-alpha on angiogenesis in a three-dimensional collagen gel-culture.
Fujita K; Asami Y; Murata E; Akita M; Kaneko K
Okajimas Folia Anat Jpn; 2002 Oct; 79(4):101-6. PubMed ID: 12484444
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide metabolism and hydrolysis: mechanisms and implications.
Lepper ER; Smith NF; Cox MC; Scripture CD; Figg WD
Curr Drug Metab; 2006 Aug; 7(6):677-85. PubMed ID: 16918319
[TBL] [Abstract][Full Text] [Related]
16. [Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19].
Li YH; Hou J; Jiang H; Huang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):102-6. PubMed ID: 19236757
[TBL] [Abstract][Full Text] [Related]
17. [Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line].
Chen W; Zhu J; Mirshahi F; Soria J; Mirshahi M; Soria C
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):520-3. PubMed ID: 12482348
[TBL] [Abstract][Full Text] [Related]
18. In vitro biotransformation of (R)- and (S)-thalidomide: application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites.
Meyring M; Mühlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G
Anal Chem; 2002 Aug; 74(15):3726-35. PubMed ID: 12175160
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties.
Périno S; Contino-Pépin C; Satchi-Fainaro R; Butterfield C; Pucci B
Bioorg Med Chem Lett; 2004 Jan; 14(2):421-5. PubMed ID: 14698173
[TBL] [Abstract][Full Text] [Related]
20. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
